

Initial Date: 4/2010 Revised Date: 03/24/2023

Section: 10-3

Nerve Agent/Organophosphate Pesticide Exposure Treatment

Purpose: This protocol is intended for EMS personnel at all levels that have been trained in the use of these devices and authorized by the medical control authority to assess and treat patients exposed to nerve agents and organophosphate pesticides utilizing the **Duo Dote/Mark I Antidote Kits** and/or a combination of auto injectors and/or nasal sprays. Administration of non-prepackaged kits is restricted to ALS.

The following medications in this protocol are not required to be carried on EMS vehicles and may be available through special response units.

Medications/Definitions:

- A. One (1) Nerve Agent (NA) Antidote Kit for the purpose of this protocol means either one (1) Duodote OR one (1) Mark I
 - 1. **Duodote** a single device with 2 chambers. The front chamber contains 2.1 mg atropine, the back chamber contains 600 mg pralidoxime (2-PAM). When activated the device sequentially administers both drugs through a single needle.
 - 2. **Mark I Antidote kit** 2 separate injectors. One containing 2mg atropine, the second containing 600 mg of pralidoxime (2-PAM).
- B. **Atropine auto injector-** a single auto-injector of atropine that comes in 3 doses: atropine 0.5 mg, atropine 1 mg, atropine 2 mg.
- C. Midazolam auto-injector 20 mg midazolam per device
- D. Midazolam nasal spray 5 mg per device
- E. Diazepam auto-injector 10 mg per device
- F. Non prepackaged kit administration: Administer 600 mg **pralidoxime** and 2 mg of **atropine** for every one (1) NA Antidote Kit.(ALS only)

Chemical Agents

- 1. Agents of Concern
 - A. Military Nerve Agents including: Sarin (GB), Soman (GD), Tabun (GA), VX
 - B. Organophosphate Pesticides (OPP) including Glutathione, Malathion, Parathion, etc.
- 2. Detection: The presence of these agents can be detected through a variety of monitoring devices available to most hazardous materials response teams and other public safety agencies.

Patient Assessment

- 1. **<u>SLUDGEM</u>** Syndrome
 - A. **S** Salivation / Sweating / Seizures
 - B. **L** Lacrimation (Tearing)
 - C. **U** Urination
 - D. **D** Defecation / Diarrhea
 - E. **G** Gastric Emptying (Vomiting) / GI Upset (Cramps)

MCA Name: HEMS, Inc. (WW/DR) MCA Board Approval Date: 2/8/2024 MCA Implementation Date: 3/1/2024 MDHHS Approval: 3/24/23



Initial Date: 4/2010 Revised Date: 03/24/2023

F.

Section: 10-3

- **E** Emesis
- G. **M** Muscle Twitching or Spasm
- 2. <u>Threshold Symptoms</u>: These are symptoms that may allow rescuers to recognize that they may have been exposed to one of these agents and include:
 - A. Dim vision
 - B. Increased tearing / drooling
 - C. Runny nose
 - D. Nausea/vomiting
 - E. Abdominal cramps
 - F. Shortness of breath

NOTE: Many of the above may also be associated with heat related illness.

- 1. Mild Symptoms and Signs:
 - A. Threshold Symptoms *plus*:
 - B. Constricted Pupils*
 - C. Muscle Twitching
 - D. Increased Tearing, Drooling, Runny Nose
 - E. Diaphoresis
- 2. Moderate Symptoms and Signs
 - A. Any or all above plus:
 - **B.** Constricted Pupils
 - C. Urinary Incontinence
 - D. Respiratory Distress with Wheezing
 - E. Severe Vomiting
- 3. Severe Signs
 - A. Any or All of Above *plus*
 - B. Constricted Pupils*
 - C. Unconsciousness
 - D. Seizures
 - E. Severe Respiratory Distress

***NOTE**: Pupil constriction is a relatively unique finding occurs early and persists after antidote treatment. The presence of constricted pupils with SLUDGEM findings indicates nerve agent / OPP toxicity. Constricted pupils may not be present with localized dermal exposure.

Personal Protection

- 1. Be Alert for secondary device in potential terrorist incident
- 2. Personal Protective Equipment (PPE)
 - A. Don appropriate PPE as directed by Incident Commander.
 - B. Minimum PPE for Non-Hot Zone (i.e., DECON Zone)
 - a. Powered Air Purifying Respirator or Air Purifying Respiratory with proper filter
 - b. Chemical resistant suit with boots
 - c. Double chemical resistant gloves (butyl or nitrile)
 - d. Duct tape glove suit interface and other vulnerable areas
- 3. Assure EMS personnel are operating outside of Hot Zone
- 4. Avoid contact with vomit if ingestion suspected off gassing possible

MCA Name: HEMS, Inc. (WW/DR) MCA Board Approval Date: 2/8/2024 MCA Implementation Date: 3/1/2024 MDHHS Approval: 3/24/23



Initial Date: 4/2010 Revised Date: 03/24/2023

Section: 10-3

- 5. Assure patients are adequately decontaminated *prior* to transport
 - A. Removal of outer clothing provides significant decontamination
 - B. Clothing should be removed before transport
 - C. DO NOT transport clothing with patient
- 6. Alert hospital(s) as early as possible

Patient Management (After Evacuation and Decontamination)

- 1. Evaluate and maintain the airway, provide oxygenation and support ventilation as needed.
- 2. NOTE: Anticipate need for extensive suctioning
- 3. Administer appropriate number of NA Antidote kits (**Duo Dote OR Mark I)** kits per Chart A. below.
 - A. NOTE: For NA kit administration only:
 - i. Adult is > 8 years of age
 - ii. Pediatrics is ≤ 8 years of age
 - B. NOTE: Medical Control contact is required prior to administration for:
 - i. Patients that meet self-administration criteria
 - ii. Patients that meet mild symptoms and signs criteria in chart below:



Initial Date: 4/2010 Revised Date: 03/24/2023

Section: 10-3

	Clinical Findings	Signs/Symptoms	Required Conditions	NA Kits To Be Delivered
SELF-RESCUE	Threshold Symptoms	 Dim vision Increased tearing Runny nose Nausea/vomiting Abdominal cramps Shortness of breath 	Threshold Symptoms -and- Positive evidence of nerve agent or OPP on site	1 NA Kit (self-rescue)
JLT PATIENT > 8 years of age	Mild Symptoms and Signs	 Increased tearing Increased salivation Dim Vision Runny nose Sweating Nausea/vomiting Abdominal cramps Diarrhea 	Aedical Control Order	1 NA Kit
ADULT PATIEN	Moderate Symptoms and Signs	 Constricted pupils Difficulty breathing Severe vomiting 	Constricted Pupils	2 NA Kits
	Severe Signs	 Constricted pupils Unconsciousness Seizures Severe difficulty breathing 	Constricted Pupils	3 NA Kits (If 3 NA Kits are used, administer 1 st dose of available benzodiazepine)



Initial Date: 4/2010 Revised Date: 03/24/2023

Section: 10-3

	Clinical Findings	Signs/Symptoms	Required Conditions	NA Kits To Be Delivered
PEDIATRIC < 8 years of age	Pediatric Patient with Non-Severe Signs/Symptoms	Mild or moderate symptoms as above	Threshold Symptoms <i>-and-</i> Positive evidence of nerve agent or OPP on site Medical Control Order	1 NA Kit
	Pediatric Patient with Severe Signs/Symptoms	 Constricted pupils Unconsciousness Seizures Severe difficulty breathing 	Severe breathing difficulty Weakness	1 NA Kit

4. Establish vascular access per **Vascular Access and IV Fluid Therapy-Procedure Protocol** when feasible, do NOT delay medication administration

- 5. If NA Antidote kit is not available:
 - A. Administer **atropine auto injector** 2 mg IM for every 1 NA Kit- that is required.
 - B. Administer atropine 2 mg IV/IM for every 1 NA Kit that is required
 - C. Administer 600 mg pralidoxime IV/IM for every 1 NA Kit that is required (when available)
- ↔ 6. Treat seizures
 - A. Adult (> 14 years of age)
 - a. Administer midazolam 10 mg IM or 5 mg IN
 - 1. If available, midazolam auto-injector or midazolam nasal spray may be utilized, ensure total dose (regardless of dosage per device) equals 10 mg IM or 5 mg IN.
 - OR
 - b. Administer Valium (diazepam) auto-injector.

B. Pediatrics (< 14 years of age)

- a. Administer **midazolam** 0.1 mg/kg IM (maximum individual dose 10 mg) or 5 mg IV/IO/or IN
 - OR
 - If available, diazepam auto-injector or diazepam nasal spray may be utilized, ensure total dose (regardless of dosage per device) does not exceed 10 mg IM or 5 mg IN.



Initial Date: 4/2010 Revised Date: 03/24/2023

Section: 10-3



- 7. Monitor EKG
- 8. For continued secretions, contact Medical Control and administer additional atropine per orders.
 - A. Adults (> 14 years of age) atropine 2 mg IV/IM

B. Pediatrics (<u><</u>14 years of age) **atropine** 0.05 mg/kg IV/IM

Nerve Agent/Organophosphate

Antidotes/Countermeasures

Weight	Age	Duodote ¹ Mod-Severe Sxs	Atropen ² (1 mg) Mod- Severe Sxs	Atropine Dose (0.1 mg/kg) IM/IV/IO	Atropine Vial ² (1 mg/mL)	Cardiac Atropine ^{2,3} (1 mg/10 mL)	Midazolam ⁴ (10 mg/2 mL) IM/IV/IO
3-5 kg (6-11 lbs)	0-2 months	1	1	0.4 mg	0.4 mL	4 mL	0.1 mL
6-7 kg (13-16 lbs)	3-6 months	1	1	0.7 mg	0.7 mL	7 mL	0.2 mL
8-9 kg (17-20 lbs)	7-10 months	1	1	0.9 mg	0.9 mL	9 mL	0.2 mL
10-11 (21-25 lbs)	11-18 months	1	1	1 mg	1 mL	10 mL	0.2 mL
12-14 kg (26-31 lbs)	19-35 months	1	2	1.3 mg	1.3 mL	13 mL	0.25 mL
15-18 kg (32-40 lbs)	3-4 years	1	2	1.6 mg	1.6 mL	16 mL	0.3 mL
19-23 kg (41-51)	5-6 years	1	2	2 mg	2 mL	20 mL	0.4 mL
24-29 kg (52-64)	7-9 years	2	3	2.6 mg	2.6 mL	26 mL	0.5 mL
30-36 kg (65-79 lbs)	10-14 years	2	3	3.3 mg	3.3 mL	33 mL	0.6 mL
Adult	>14 years	2 to 3	4 to 6	4 to 6 mg	4 to 6 mL	40-60 mL	2 mL

¹Preferred initial autoinjector, ²May Repeat atropine every 5 minutes until airway secretions decrease (6 mg maximum), ³Not available in MEDDRUN, ⁴Patients with severe symptoms should receive midazolam even if not obviously seizing

<u>Medication Protocols</u> Atropine Midazolam Nerve Agent Antidote Kit Pralidoxime